- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1257628-77-5] Olverembatinib
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-15666 |
| Brand: | MCE |
| CAS: | 1257628-77-5 |
Overview
| MDL | MFCD26142930 |
|---|---|
| Molecular Weight | 532.56 |
| Molecular Formula | C29H27F3N6O |
| SMILES | O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C(NN=C5)C5=C4)=C3 |
2 Publications Citing Use of MCE
Summary
Olverembatinib (GZD824) is a potent and orally active pan- Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC 50 s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity [1] .
IC50 & Target
IC50: 0.68 nM (Bcr-Abl T315I ), 0.27 nM (Bcr-Abl E255K ) , 0.71 nM (Bcr-Abl G250E ) , 0.15 nM (Bcr-Abl Q252H ), 0.35 nM (Bcr-Abl H396P ), 0.29 nM (Bcr-Abl M351T ), 0.35 nM (Bcr-Abl Y253F ), Bcr-Abl F317L [1]
In Vitro
Olverembatinib shows antiproliferative activity in stably transformed Ba/F3 cells whose growth was driven by native Bcr-Abl or Bcr-Abl mutants
[1]
.
Olverembatinib selectively and potently inhibits the proliferation of Bcr-Abl-positive leukemia cells
[1]
.
Olverembatinib inhibits Bcr-Abl signaling in K562 (1-20 nM; 4.0 hours) and Ba/F3 stable cell lines expressing native Bcr-Abl (0.1-100 nM; 4.0 hours) or Bcr-Abl
T315I
(0.1-100 nM; 4.0 hours)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | K562 cells |
| Concentration: | 1 nM, 2 nM, 5 nM, 10 nM, 20nM |
| Incubation Time: | 4.0 hours |
| Result: | Inhibited Bcr-Abl signaling in K562 cell lines. |
In Vivo
Olverembatinib suppresses tumor growth in mice bearing allografted Ba/F3 cells expressing Bcr-Abl
WT
[1]
.
Olverembatinib (1-20 mg/kg; i.g.; daily; for 10 days) significantly increases the median survival of the mice bearing allografted Ba/F3 cells expressing Bcr-Abl
T315I
[1]
.
Olverembatinib exhibits a good oral bioavailability (rat 48.7%) and C
max
(rat 390.5 μg/L) following oral administration (rat; 25 mg/kg)
[1]
.
Olverembatinib exhibits terminal elimination half-lives (rat 5.6 h) due to high plasma clearance (rat 1.7 L/h/kg) following intravenous administration (rat 5 mg/kg)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SCID nude mice, bearing allografted Ba/F3 cells expressing Bcr-Abl T315I [1] |
| Dosage: | 1 mg/kg, 2 mg/kg, 5.0 mg/kg, 10 mg/kg, 20 mg/kg |
| Administration: | Oral gavage, daily, for 10 days |
| Result: | Efficiently prolonged animal survival in an allograft leukemia tumor model. |
| Animal Model: | Rats [1] |
| Dosage: | 5 mg/kg for i.v.; 25 mg/kg for oral (Pharmacokinetic Analysis) |
| Administration: | Intravenous injection and oral administration |
| Result: | Oral bioavailability (48.7%), C max (390.5 μg/L), T 1/2 (5.6 h). |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04126681 | Ascentage Pharma Group Inc.|HealthQuest Pharma Inc. |
Chronic Myeloid Leukemia, Chronic Phase
|
October 21, 2019 | Phase 2 |
| NCT05594758 | Ascentage Pharma Group Inc.|Tanner Pharma Group |
|
||
| NCT05466175 | Chen Suning|The First Affiliated Hospital of Soochow University |
Philadelphia-Positive ALL
|
October 1, 2022 | Phase 2 |
| NCT03883087 | Ascentage Pharma Group Inc. |
Chronic Myeloid Leukemia, Chronic Phase
|
April 8, 2019 | Phase 2 |
| NCT05521204 | The First Affiliated Hospital of Soochow University |
Myeloproliferative Neoplasm|Acute Leukemia
|
September 1, 2022 | Phase 2 |
| NCT04260022 | Ascentage Pharma Group Inc. |
Leukemia, Myeloid, Chronic|Myeloid Leukemia|Chronic Myeloid Leukemia|Philadelphia Positive Acute Lymphoblastic Leukemia|B Cell Precursor Type Acute Leukemia
|
January 9, 2020 | Phase 1 |
| NCT05603156 | Institute of Hematology & Blood Diseases Hospital |
Ph&addition; ALL|Bone Marrow Transplant|Minimal Residual Disease
|
October 30, 2022 | Not Applicable |
| NCT03882281 | Ascentage Pharma Group Inc.|HealthQuest Pharma Inc. |
Chronic Myeloid Leukemia, Chronic Phase
|
March 25, 2019 | Phase 1 |
| NCT05311943 | Shenzhen Second People´s Hospital |
Olverembatinib|Chronic Myeloid Leukemia, Chronic Phase|Tyrosine Kinase Inhibitors
|
July 1, 2022 | Phase 3 |
| NCT05376852 | Nanfang Hospital of Southern Medical University |
Chronic Myeloid Leukemia in Myeloid Blast Crisis|Chronic Myeloid Leukaemia Transformation|Chronic Myeloid Leukemia - Accelerated Phase|Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)
|
December 1, 2021 | Phase 2 |
| NCT05604755 | xuna|Nanfang Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Guangdong Second Provincial General Hospital |
Prophylactic HQP1351 Therapy|Third Generation TKI
|
January 1, 2022 | Phase 2 |
| NCT03883100 | Ascentage Pharma Group Inc. |
Chronic Myeloid Leukemia - Accelerated Phase
|
April 8, 2019 | Phase 2 |
| NCT03594422 | Ascentage Pharma Group Inc.|HealthQuest Pharma Inc. |
Gastrointestinal Stromal Tumor (GIST)|Solid Tumor, Adult
|
July 11, 2018 | Phase 1 |
| NCT04126707 | Ascentage Pharma Group Inc.|HealthQuest Pharma Inc. |
Chronic Myeloid Leukemia (CML)
|
November 19, 2019 | Phase 1 |
| NCT05594784 | Institute of Hematology & Blood Diseases Hospital |
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
|
October 8, 2022 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 41.67 mg/mL ( 78.24 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8777 mL | 9.3886 mL | 18.7772 mL |
| 5 mM | 0.3755 mL | 1.8777 mL | 3.7554 mL |
| 10 mM | 0.1878 mL | 0.9389 mL | 1.8777 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.